Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Jennifer L. Davis resigning as Class II director effective November 2, 2026.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jennifer L. Davis resigning as Class II director effective November 2, 2026
- Departure follows her appointment as Align Technology CEO
- No dispute or disagreement with AbbVie cited
- Board vacancy and potential succession or committee reassignment implications for shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.